- An Arm and a Leg: The Accidental Architect of America’s Drug Patent Problem
- In Connecticut, Doctors Now Sue Patients Most Over Medical Bills, Surpassing Hospitals
- Trump orders FDA to fast-track reviews of psychedelic drugs after lobbying by podcaster
- DOJ seeks immediate asset freeze, receivership against telehealth company Zealthy
- New Clues Explain Why Immunotherapy Fails in Pancreatic Cancer
- Does My Child Have a Language Disorder?
- Journalists Talk Hot Health Topics: Urgent Care Clinics Performing Abortions and Doulas’ Pay
- ASCs’ vendor problem
- Providence’s physician chief on its ‘holistic’ approach to value-based care
- What the Health? From KFF Health News: A New CDC Nominee, Again
- States Update Guardianship Laws To Keep Children of Immigrants Out of Foster Care
- Anesthesia job market faces ‘major disruption’
- Florida system raises $100M for new ED
- North Carolina system names COO
- Mark Cuban wants to bring drug manufacturing to hospitals’ doorsteps — literally
- UCI Health names chief AI officer
- Nevada hospital names CEO
- Saint Luke’s taps president for 2 hospitals
- Dental community mourns dentist killed in murder-suicide
- Mass General Brigham, CVS deal could raise healthcare spending $40M annually: Report
- Ideal Dental opens 1st Oklahoma practice, expands in 2 more states
- PDS Health eyes the next era of medical-dental integration
- Mark Cuban dives into direct contracting
- HCA executive pay by the numbers
- Iris Telehealth offers behavioral health analytics platform
- HHS names chief economist, regulatory leader to address healthcare affordability
- Loma Linda University Health names new president
- The best ASCs for colonoscopy, endoscopy in the South: US News
- Tennessee moves forward with CON repeal
- Dental schools take action to alleviate workforce shortages: 6 updates
- American Medical Group Association partners with Talkiatry to expand psych access
- Trump nominates CDC director
- ChristianaCare, Cardiovascular Physicians of Delaware to open joint venture ASC
- 5 states regulating AI in mental health
- Centerstone debuts $13M youth behavioral health campus in Missouri
- 3 DSOs making headlines
- Maine restricts noncompetes for rural healthcare workers
- Heartland Dental opens Florida office
- The 10 biggest ASC deals of the last 5 years
- Affordability, transparency: A look at large employers' top healthcare concerns
- 10 dental Medicaid updates to know from Q1
- White House eyes ibogaine research expansion
- New Weight Loss Research Questions Need for GLP-1 Drugs
- Trump Names CDC Director Pick
- SocialRx teams up with FQHC in NYC to prescribe arts and culture for chronically ill patients
- FDA To Review Whether To Allow More Access To Certain Peptides
- Rising Colon Cancer Deaths Hit Younger Adults Without Degrees Hardest
- The Healthccare Burnout Backlask (pt 4): Why Contract Negotiation Has Become a Core Strategic Skill for Healthcare Administrators
- The Healthccare Burnout Backlask (pt 4): Why Contract Negotiation Has Become a Core Strategic Skill for Healthcare Administrators
- Over 80% of PCPs concerned about financial stability over next several years
- Industry Voices—DOJ jumps into 340B cases over state law, raising questions about federal plans for the program
- FDA's accelerated approval pathway needs stronger transparency, evidence standards: ICER
- Most People Would Take A Blood Test For Alzheimer's, Study Says
- This Sexually Transmitted Infection Linked To Heart Attack, Stroke
- How Playtime at Age 2, Especially with Parents, Shapes Teen Fitness Habits
- New Depression Treatment Matches ECT with Less Memory Loss, Study Says
- Memory Problems? Your Salt Intake Could Make Matters Worse, Study Says
- Ultra-Processed Foods Linked To Fatty Muscles, Potential Knee Arthritis
- Your New Therapist: Chatty, Leaky, and Hardly Human
- Teva scores in appeal as court revives $177M verdict against Lilly in migraine patent spat
- Gen AI chatbots continually struggle with differential diagnoses, Mass General Brigham study finds
- Listen: With Little Federal Regulation, States Are Left To Shape the Rules on AI in Health Care
- Fierce Pharma Asia—Astellas’ stem cell therapy rethink; GSK’s bullish ADC plan; Daiichi’s OTC sale
- BIO comes out swinging with 'Fight of Our Lives' campaign for the industry’s 50th birthday
- The future of medical-dental integration is here
- Texas dentist has license suspended
- Efforts grow to limit corporate dental ownership, protect dentist autonomy: 6 updates
- What’s the deal with insurer mental health parity violations?
- Remarks at the Options Market Structure Roundtable
- Wider care gaps predicted as mental health parity rule faces rollback
- Sheppard Pratt gets $16.5M for behavioral health expansion
- Former Deputy Surgeon General Erica Schwartz, M.D., nominated as CDC director
- Verily Health simplifies medical jargon alphabet soup with AI-powered app in new campaign
- 10 trends in behavioral health usage: Report
- Cattywampus: Statement on the CAT Concept Release
- Providers' advantage on out-of-network billing disputes likely to continue: Capstone
- Butterflies and Condors: Remarks at the Options Market Roundtable
- Viatris, Teva kick off separate recalls over dissolution, raw material issues
- Mental health ED visits at Children’s Hospital Colorado jump 20% in April
- Rising ACA Costs Leave Many Unable To Pay for Coverage
- One Lot of Xanax Recalled Nationwide Over Quality Issue, FDA Says
- Cough Drops From Several Brands Being Recalled, FDA Says
- CDC May Get New Leader as Officials Consider Erica Schwartz
- Statement at the Roundtable on Options
- Opening Remarks at the Options Market Structure Roundtable
- APA launches resource library for trusted digital mental health tools
- E-Bikes And E-Scooters A Growing Menace On City Streets, Study Says
- 'Absent or trivial' effects: Anti-amyloid Alzheimer's drugs called into question once again
- RFK Jr. kicks off string of congressional hearings to talk White House budget plan
- This Simple Step Could Improve The Benefits From Your Regular Workouts
- New Alzheimer's Drugs Provide No Meaningful Benefit, Major Evidence Review Concludes
- Air Pollution and Weather Tied to Migraines
- Study Says Stress, Weight And Hormones Alter Timing of Puberty in Girls
- Why Walking Remains Unsteady After Partial Spinal Cord Injury
- Roche to launch another Elevidys study after EU rejection of Duchenne gene therapy
- Lilly answers FDA's call for more Foundayo safety info, plotting diabetes filing in parallel
- As US Birth Rate Falls, Feds’ Response May Make Pregnancy More Dangerous
- New Federal Medicaid Rules Require One Month of Work. Some States Demand More.
- Omnicom brews Olixir from FCB Health, rebranding storied agency after Interpublic takeover
- DiMe-led initiative brings together pharma, virtual providers, digital pharmacies to develop blueprint for DTC pharma models
- UPDATED: Heeding RFK Jr.'s call, FDA reclassifies 12 unapproved peptides ahead of advisory committee meeting
- Carrot launches proprietary AI platform for personalized fertility, family care
- UC Health workers plan open-ended, system-wide strike for May 14
- Baylor Scott & White Health Plan to depart individual market, Medicaid this year
- In industry's latest OTC pivot, Daiichi Sankyo lines up $1.5B consumer health unit sale to beverage giant Suntory
- Brain Cancer Awareness: The Importance of Molecular Testing for Patients with Rare Brain Tumors
- EPA Delays Decisions on 'Forever Chemicals'
- Wildlife Trade Tied To Higher Risk of Diseases Spreading to Humans
- Yes, This is the Worst Pollen Season Ever — Until Next Year
- GoodRx launches 7.2-mg Wegovy dose for self-pay patients at $399 per month
- Progyny unveils new fertility benefit option for small, mid-size employers
- Providers back bipartisan bill eliminating Medicare chronic care management cost sharing
- New Weight Loss Pill, Foundayo, Gets Approval But FDA Seeks More Safety Data
- Seqster launches new data tool to turn clinical sites into 'research-ready data collection points'
- Gilead widens global Yeztugo access agreement, but MSF says supply is 'not nearly enough'
- Novartis CEO Vas Narasimhan joins Anthropic’s board as biopharma’s ties to AI deepen
- Behavioral health utilization is up with anxiety disorders leading demand, report finds
- Does Your Child Have A Concussion? These Are The Signs, Review Says
- AI Reveals Negative Labels in Medical Records for Sickle Cell Patients
- 'Food-as-Medicine' Improves Life for Heart Failure Patients
- Silent Heart Rhythm Problem Might Triple Risk Of Heart Failure In Seniors
- Blood Test Predicts Alzheimer's Years Before Symptoms, Brain Changes
- An Infectious Combo Triples Risk Of MS, Study Says
- Astellas manufacturing chief views reliable supply, bridging research as his production 'north star'
- Physician compensation up 3% in 2025, but not all specialties saw raises: Medscape
- Pfizer recruits former Angel Lucy Liu for latest mission against cancer
- Teva launches new online schizophrenia community project
- One man’s journey from gambling addiction to recovery and advocacy
- Rural Nebraska Dialysis Unit Closes Despite the State’s $219M in Rural Health Funding
- Ionis exec shares method to the Madness after 2026 Drug Name Tournament win
- Abridge expands clinical decision support solution with UpToDate partnership, new NEJM, JAMA content tie-ups
- Travere maps course for Filspari's $3B US opportunity after landmark rare disease nod
- FDA tells Eli Lilly to round up more safety info on key obesity launch Foundayo
- Meat Consumption Rises as Protein Trend Grows, Experts Warn
- Bill would force payers to apply DTC drug purchases to patient deductibles
- Nuts.com Recalls 10,000+ Pounds of Candy Over Allergy Risk
- Keebler Health secures $16M in series A funding for AI-powered risk adjustment platform
- Sam’s Club Recalls Children’s Pajamas Due to Fire Hazard
- Small Talk? It May Be Better Than You Think
- J&J, chasing $100B year, sports immunology ‘dual powerhouse’ of Tremfya and new launch Icotyde
- Long-Term Opioid Prescriptions Fall By About A Quarter
- Gut Bacteria Might Drive Rare Food Allergy in Children, Study Finds
- Stents Can Ease Long-Term Symptoms Of Deep Vein Thrombosis, Trial Shows
- Young Cancer Survivors Face Doubled Risk Of Subsequent New Cancer
- FDA Reminds More Than 2,200 Sponsors and Researchers to Disclose Trial Results
- FDA Reminds More Than 2,200 Sponsors and Researchers to Disclose Trial Results
- Freedom of Associations
- Interfacing with our Inner Demons: Comments on the Division of Trading and Markets' Statement on Certain User Interfaces
- Staff Statement Regarding Broker-Dealer Registration of Certain User Interfaces Utilized to Prepare Transactions in Crypto Asset Securities
- Statement Regarding Staff No-Action Letter to Bank of England
It would appear that the "Hands Off My Medicare" crowd attacking RFK, Jr. and the Trump Administration have been waxing delusional:
https://www.fiercehealthcare.com/payers/cms-finalizes-506-medicare-advantage-benchmark-increase
CMS finalizes 5.06% Medicare Advantage benchmark increase
By Noah Tong - April 7, 2025The Centers for Medicare and Medicaid Services (CMS) finalized an increase of the average benchmark payments to Medicare Advantage (MA) plans by 5.06% on Monday.
It is nearly a three percentage-point increase over the advance notice proposed in the waning days of the Biden administration and will be seen as favorable to payers. CMS said this is due to the effective growth rate increase from 5.93% to 9.04% in the rate announcement.
“This change is primarily due to the inclusion of additional data on fee-for-service (FFS) expenditures, including payment data through the fourth quarter of 2024, which was not included on account of the early Advance Notice publication,” the agency said in a news release.
Rebasing and re-pricing ultimately brought the payments to plans down by approximately a quarter of a percent.
UnitedHealth Group stock increased by 6% in after-hours trading over its day-end closing price, following brutal days for the stock market because of tariff-induced challenges. CVS Health jumped by 9%, Elevance Health by 8% and Humana by 16%. Insurtechs Clover Health Alignment Healthcare increased by 6% and 9% respectively.
CMS will also finish phase-in of the MA risk adjustment model, and continue the phased-in approach for removing medical education costs from expenditures in growth rate calculations. Most insurers asked for the risk adjustment model to be paused.
The rate increase was supported by Medicare Advantage advocate Better Medicare Alliance and the Alliance for Community Health Plans (ACHP). The ACHP was one of the few insurer groups to support the new risk adjustment model and did not want it delayed.
"ACHP commends the Trump administration for finalizing policies in the [rate notice] that reflect higher care delivery costs and for taking another step toward reining in aggressive risk adjustment to boost competition," said President and CEO Ceci Connolly in a statement. "ACHP has long supported the new MA risk adjustment model and is pleased that CMS will finally complete the transition."
In January, CMS released the proposed rate, which would have increased payments by 2.23% and continued implementation of the risk adjustment model. Payments from the federal government would have increased by $21 billion, or 4.33%, the CMS said.
Doctors criticized the proposed rate, arguing insurers were once again receiving preferential treatment from the federal government. Providers and physicians said Congress still hasn't reversed painful doc pay cuts implemented by CMS as required by prior statute—and yet insurers were in line to get a boost.
The physician pay reversal was included in an end-of-the-year healthcare package before the bill failed at the eleventh hour due to other political considerations. It was again rejected in an effectively symbolic introduction by Senators Ron Wyden, D-Oregon and Bernie Sanders, I-Vermont before the Senate agreed to a government funding bill.
The insurance lobby criticized Biden’s health officials during his tenure for enacting tougher rates on plans, so the 2.23% rate was more favorable to payers than initially expected. In 2024, the government finalized a cut of 0.16% to MA plans.
Starting Jan. 1, annual out-of-pocket prescription drug costs were capped at $2,000 for enrollees.
CMS recently released its Contract Year 2026 MA and Part D final rule, choosing to punt on implementing agent and broker marketing requirements, most star ratings changes and imposing new guardrails on AI. The rule also declined to adopt a Biden-supported policy to have Medicare and Medicaid cover anti-obesity drugs, but did include new requirements on prior authorization and Special Supplemental Benefits for the Chronically Ill.
Left of center Morning Brew brings some additional macro market perspective.
https://www.healthcare-brew.com/stories/2025/04/09/cms-hikes-medicare-advantage-payments
CMS hikes Medicare Advantage payments up 5%, over $25b
Government payments to MA plans are set to rise over $25b in 2026—and Wall Street noticed.
By Caroline Catherman | April 9, 2025The federal government is going to pay Medicare Advantage (MA) plans a lot more in 2026.
In payment policy updates released on Monday evening, the Centers for Medicare and Medicaid Services (CMS) said MA plans will receive average payment increases of 5.06%—or more than $25 billion—from 2025 to 2026. This is 2.83 percentage points higher than CMS had predicted in its January advance notice of these changes, and more than double the 2.33% increase it had estimated from 2024 to 2025.
“This was the administration’s first chance to pump the brakes on MA, and there was some uncertainty going into the release. The rate notice indicates a desire to drive on—and maybe accelerate,” Luke Hansen, chief medical officer at Arcadia, a healthcare data platform for payers and providers, told Healthcare Brew.
For 2025, the Medicare Payment and Advisory Commission predicted the federal government will pay MA plans $538 billion. (In 2024, it paid $494 billion, per the commission.)
Though the stock market is largely a burning dumpster fire right now, MA providers’ shares are soaring after the news.
The largest MA provider, UnitedHealthcare, saw its stock jump from $524.70 at market close on Monday to $582.17 at market open on Tuesday, though the stock came down to around $553.08 by the day’s end.
Why so high? CMS said on April 7 that the rate increase is “largely attributable” to an increase in the effective growth rate. This rate represents the average expected change in MA benchmarks, which is the maximum amount the government will pay each Medicare Advantage plan, according to independent research nonprofit the Commonwealth Fund.
Benchmarks are calculated using the average spending in traditional fee-for-service Medicare in each county. That data wasn’t complete for 2024 when CMS estimated a 5.93% effective growth rate in its 2026 advance notice. Now, with the data complete, the effective growth rate is 9.04%, CMS said.
Zooming out. The rate updates and 2026 guidance were released just days after Congress approved Mehmet Oz as the new CMS director on April 3.
The New York Times reported in February that Oz has financial ties to Medicare Advantage companies, like TZ Insurance, sparking concerns about potential conflicts of interest. But during congressional confirmation hearings, Oz addressed bipartisan concerns about prior authorization and overpayment.
CMS will also in 2026 complete reforms to the MA risk adjustment model, which is intended to reduce overpayments, and finalize guidance on the Inflation Reduction Act’s Part D changes, including the Medicare Drug Price Negotiation Program.
Get MHF Insights
News and tips for your healthcare freedom.
We never spam you. One-step unsubscribe.














